click below
click below
Normal Size Small Size show me how
ACS
Acute Corinary Syndrome
Drug Name | Class | Who gets it? |
---|---|---|
eptifibatide (intergrilin) | Glycoprotein IIb/IIIc receptor antagonists (antiplatelet agent) | renal cleared IV during PCI and 12-24 hours afterward |
tirofiban (aggrestat) | Glycoprotein IIb/IIIc receptor antagonists (antiplatelet agent) | renal cleared IV during PCI and 12-24 hours afterward. AE bleeding thrombocytopenia monitor hematocrit and platelet counts |
UFH | antithrombin agent | for 48 hours |
Enoxaparin | antithrombin agent | not renal failure or dialysis BID daily preferred (or fond) in low risk and being treated with conservative medical strategy |
bivalirudin | antithrombin agent direct thrombin inhbitor | preferred agent if HIT present or suspected. doesn't require the use of Gpp IIb/IIIa receptor during PCI if this is used. not used in conservative treatment. reduced risk of bleeding compared to LMWH and UFH. can be continued for duration of stay |
fondaparinux | antithrombin agent | not in CrCL <30 mL/min. not recommended at time of PCI because will need another agent. preferred with enox, in low risk and being treated with conservative medical strategy |
oxygen | lower than 80 | |
aspirin 325 | ||
morphine | those with refractory angina as analgesic and venodilator that lowers preload | |
IV metoprolol avoid IV when at risk for shock | beta blocker | decrease rate and oxygen demand, get it if don't show evidence of acutely low out put, no peripheral edema, JVD, rales of S3 heart sounds. give oral if SPB not >160 |
streptokinase (streptase) | thrombolytic | potential antigenicity, Ci with prior exposure greater than 5 days |
anistrepalse (aminase) | thrombolytic | potential antigenicity, CI with prior exposure greater than 5 days |
alteplase (activase) | thrombolytic | |
reteplase (retavse) | thrombolytic | genetically modified plasminogen activator similar to t-PA with longer half life |
tenecteplase (TNK) | thrombolytic | high fibrin specificity longer half life and higher resistance to inhinbition by plasminogen activator inhibitor |
urokinase | non popular thrombolytic | |
abciximab (reoPro) | Glycoprotein IIb/IIIc receptor antagonists (antiplatelet agent) |